Success Story: Pakistani Research Postdoc Fellow Earns EB1A Approval for Advancing Cardiorenal and Population Health Research
Client’s Testimonial:
“I am pleased to share my experience with Chen. They did a wonderful job in preparing my petition, drafting the letters, and providing guidance throughout my EB1 and EB2 journey. While I provided them with the papers that cited my research, all my publication record, and every other achievement, their ability to organize everything into a compelling petition was truly outstanding. The final petition and recommendation letters were very strong and well-written. I have already recommended Chen Law to my friends and colleagues, but I would definitely suggest it to anyone seeking a reliable lawyer and a strong petition.”
On November 25th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Research Postdoc Fellow in the field of Cardiorenal Syndrome (Approval Notice).
General Field: Cardiorenal Syndrome
Position at the Time of Case Filing: Research Postdoc Fellow
Country of Origin: Pakistan
State of Residence at the Time of Filing: Texas
Approval Notice Date: November 25th, 2025
Processing Time: 15 days (Premium Processing Requested)
Case Summary:
We are pleased to share the EB1A approval of a research postdoc fellow from Pakistan whose work advances cardiovascular and kidney disease research. At the time of filing, the client was conducting population-level studies examining heart failure, chronic kidney disease, cancer-associated cardiac decline, and cardiovascular risk patterns. His findings improve clinical decision-making, support early prevention strategies, and strengthen national capacities for disease surveillance. With an exceptional publication record, extensive citation impact, and significant peer review service, he presented a compelling case for EB1A approval.
Extraordinary Research Contributions
The client’s research clarifies epidemiologic trends and treatment outcomes across major cardiovascular and renal conditions. His contributions to global disease burden assessments and cardiorenal epidemiology have informed policy development and improved understanding of risk factors that shape clinical outcomes. His studies are widely cited and used across cardiology, nephrology, and public health research, demonstrating their substantial influence.
Academic Record and Recognition
The client has documented his work in 36 peer-reviewed journal articles, 9 abstracts, and 16 peer-reviewed collaboration/consortium papers, earning 8,706 citations worldwide. His publications appear in notable journals within cardiovascular, renal, and epidemiologic research. He has completed more than 40 peer reviews and serves on the editorial board of PLoS One, reflecting recognition of his expertise and standing in the scientific community.
Expert Endorsements
Independent experts emphasized the clinical and societal relevance of his work.
One recommender stated:
“…it is clear that [Client] is a respected figure in the cardiorenal syndrome field who has augmented clinical treatment practices and public health policies for better cardiovascular disease prevention and management in the U.S.”
This testimony highlights both the national value and scientific significance of his contributions.
EB1A Approval and Outlook
The I-140 EB1A petition was filed on November 10, 2025, and approved on November 25, 2025, under premium processing. With NAILG’s support, the client demonstrated extraordinary ability through his influential publications, citation impact, and contributions to cardiorenal research.
He now continues his work in the United States, advancing cardiovascular and renal epidemiology to support public health innovation and reinforce the United States’ leadership in disease prevention and clinical research.